Benzinga··Vandana SinghGSK Acquires 35Pharma for $950M to Strengthen Pulmonary Hypertension Portfolio
GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.
GSKRAPTacquisitionclinical development